Karmustin Teva

Carmustine, the active ingredient in Karmustin, is an alkylating agent presented as an intravenous solution for intravenous use. It is employed in the treatment of several malignant neoplasms, including primary brain tumors and various lymphomas. GNH USA supplies Karmustin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Carmustine is an alkylating chemotherapy used primarily for malignant solid tumours and lymphoid cancers. - Glioblastoma multiforme: provides cytotoxic activity to reduce tumor growth and improve survival. - Hodgkin's lymphoma: contributes to disease remission when combined with multi‑agent regimens. - Non‑Hodgkin's lymphoma: offers tumor cell kill as part of combination chemotherapy. - Melanoma: used in advanced disease to achieve disease control. - Multiple myeloma: incorporated into protocols to target plasma‑cell proliferation.

Carmustine may cause a range of adverse reactions that vary in frequency and severity. Common Side Effects: - Nausea and vomiting: often managed with antiemetics. - Myelosuppression: decreased white blood cells, platelets, and red cells. - Alopecia: temporary hair loss during treatment cycles. - Fatigue: generalized tiredness common during therapy. - Pulmonary toxicity: mild interstitial changes detectable on imaging. Serious or Rare Side Effects: - Severe pneumonitis: may progress to respiratory failure. - Hepatic dysfunction: elevated liver enzymes or cholestasis. - Seizures: especially in patients with brain involvement. - Secondary malignancies: rare long‑term risk of therapy‑related cancers.

Carmustine requires careful monitoring and specific safety measures before and during therapy. - Monitor blood counts: perform complete blood count before each infusion and as clinically indicated. - Assess pulmonary function: obtain baseline lung tests and repeat periodically, especially after cumulative doses. - Avoid concurrent thoracic radiation: combined treatment increases risk of severe lung toxicity. - Use prophylactic antiemetics: to reduce nausea and vomiting associated with infusion. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake the solution.

Carmustine can interact with other medicines, altering efficacy or toxicity. Major Interactions (Avoid): - Concurrent alkylating agents: markedly increase myelosuppression risk. - Thoracic radiation therapy: synergistic pulmonary toxicity. - High‑dose corticosteroids: may exacerbate immunosuppression. Moderate Interactions (Monitor Closely): - CYP450 inducers (e.g., rifampin): may reduce carmustine exposure. - Nephrotoxic drugs (e.g., cisplatin): increase renal adverse effects. - Hepatotoxic agents (e.g., azole antifungals): heighten liver toxicity potential.